Femasys Stock (NASDAQ:FEMY)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.93

52W Range

$0.69 - $1.80

50D Avg

$1.06

200D Avg

$1.18

Market Cap

$27.43M

Avg Vol (3M)

$318.80K

Beta

-2.61

Div Yield

FEMY Company Profile

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 18, 2021

Website

FEMY Performance

FEMY Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$1.63M	$1.07M	$1.21M
Operating Income	$-17.79M	$-14.51M	$-11.60M
Net Income	$-18.82M	$-14.25M	$-11.39M
EBITDA	$-20.11M	$-13.17M	$-10.49M
Basic EPS	$-0.85	$-0.93	$-0.97
Diluted EPS	$-0.85	$-0.93	$-0.97

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
NEPH	Nephros, Inc.
PDEX	Pro-Dex, Inc.
POCI	Precision Optics Corporation, Inc.
KRMD	KORU Medical Systems, Inc.
UTMD	Utah Medical Products, Inc.